Constarium
← Search

Data · dataset · 2026

Identification and bioactivity assessment of a host-defence peptide, QUB-2654, from the skin secretion of the frog, Agalychnis callidryas

Listed in ZivaHub and Deakin Research Online and DMU Figshare and UCL Research Data Repository — shown once because both records carry DOI 10.17034/32633370.v1

Amphibian skin secretions contain a wide array of antimicrobial peptides with biological activities, providing an effective first-line of defence against microbial invasion.

Description

This thesis aims to characterise an antimicrobial peptide from the skin secretion of the Central American red-eyed tree frog, Agalychnis callidryas and to study its biological properties. Firstly, the cDNA sequence encoding an antimicrobial peptide (QUB-2654) precursor, was identified from the frog skin secretions extracted mRNAs through rapid-amplification of cDNA ends (RACE) PCR, molecular cloning and Sanger sequencing strategies.

Next, the peptide was synthesised using a solid-phase peptide synthesiser, purified by reversed-phase high-performance liquid chromatography and corroborated by MALDI-TOF mass spectrometry. The purified peptide was tested for its antimicrobial activity, anti-lung cancer cell activity and haemolytic effect, by a series of bioassays. This study showed that QUB-2654 had significant bacteriostatic and bactericidal activities against a Gram-positive bacterium, Staphylococcus aureus (ATCC-CRM 6538) (MIC=3.125 µM, MBC=6.25 µM) and a Gram-negative bacterium, Escherichia coli (ATCC-CRM 8739) (MIC/MBC=6.25 µM), but the MIC value against Candida albicans (ATCC-CRM 10231) was not detected even at the highest peptide concentration.

Read the rest (1 more)

In addition, QUB-2654 statistically demonstrated anti-proliferative and killing effects against NCI-H838 human lung cancer cells at and above a concentration of 10 µM. The peptide concentration required to achieve half-maximal inhibition (IC50) of the NCI-H838 cells was 11.32 µM. This peptide was not haemolytic (<5% haemolysis) at the MBC values for S.aureus and E.coli, and at the IC50 value for NCI-H838 cells. These results suggest that peptide QUB-2654 has the potential to be developed as an antibacterial and anticancer drug.<br><br><i>Thesis is embargoed until 31 December 2027.</i>

Links

Where it is published

Catalogue records · 1

Topics

Inferred from text
Cancer 75% · Mass spectrometry 75% · Sequencing 75%
Provenance · 4 source records, 16 field assertions
SourceKeyLast seenRaw
ZivaHuboai:figshare.com:article/3263337012 d agoJSON v1
Deakin Research Onlineoai:figshare.com:article/3263337012 d agoJSON v1
DMU Figshareoai:figshare.com:article/3263337012 d agoJSON v1
UCL Research Data Repositoryoai:figshare.com:article/3263337012 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[disease].local:disease:cancerenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
concepts[field].local:field:earth-environmentalmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:earth-environmentalmapping · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · figshare dmu ac ukconnector:figshare_dmu_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:medicine-healthmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:medicine-healthmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:medicine-healthmapping · figshare dmu ac ukconnector:figshare_dmu_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · rdr ucl ac ukconnector:rdr_ucl_ac_uk@1.0.0
concepts[modality].local:modality:mass-spectrometryenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
concepts[modality].local:modality:sequencingenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
descriptionsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/description
license_textsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
publication_datesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
titlesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/title